UK Medical Devices Agency (MDA) praises Amerlite Processing Center
This article was originally published in Clinica
Johnson & Johnson's automated Amerlite Processing Center is a significant advance on the previous system, says a UK Medical Devices Agency evaluation. The reviewers did experience some assay problems but said these would only affect a few samples. Most kits showed robustness and good calibration curve stability for at least six weeks. All except the oestradiol assay had imprecision under 10% and heterophilic antibodies only affected tests at high concentrations.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.